FIG. 3.
AML-2 protein levels increase after activation of EBNA-2 in EREB2.5 cells and after EBV infection of primary B cells. (A) EREB2.5 cells were treated as described in Fig. 2 and analyzed for the expression of AML-2 and LMP-1. The blot was then stripped and reprobed with an anti-AML-1 antibody. (B) The indicated cell lines were maintained in the presence or absence of estrogen for 5 days. Extracts were analyzed by Western blotting for AML-2 or LMP-1 expression. (C) Purified B cells were isolated by CD19-positive selection and were left uninfected, were infected with EBV, or were stimulated with PMA for 48 h. RIPA lysates were prepared, and 50 μg of protein was analyzed by SDS-PAGE.